Docetax Indications/Uses

Breast Cancer: In combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer and operable node-negative breast cancer.
In combination with doxorubicin for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic chemotherapy for this condition.
As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Prior chemotherapy should have included an anthracycline or an alkylating agent.
In combination with trastuzumab, for the treatment of metastatic breast cancer whose tumors over express HER2 and without prior chemotherapy for metastatic disease.
In combination with capecitabine, for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
Non-Small Cell Lung Cancer (NSCLC): As monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of prior chemotherapy.
In combination with cisplatin, for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.
Ovarian Cancer: For the treatment of patients with metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.
Prostate Cancer: In combination with prednisone or prednisolone, for the treatment of patients with androgen independent (hormone-refractory) metastatic prostate cancer.
Gastric Cancer: In combination with cisplatin and 5-fluorouracil (5-FU), for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Squamous Cell Carcinoma of the Head and Neck (SCCHN): In combination with cisplatin and 5-FU, for the induction treatment of patients with locally advanced SCCHN.
As monotherapy, for the treatment of patients with recurrent and/or metastatic SCCHN after failure of previous chemotherapy.